Skip to main content
SpringerLink
Log in

Pulmonary Vasculitides

  • Chapter
  • First Online:
The Thorax

  • 643 Accesses

Abstract

Vasculitides refer to a heterogeneous set of diseases that are characterized by inflammation of vessel walls that leads to vessel narrowing, necrosis, obliteration, and subsequently to tissue ischemia. Vasculitis can be primary or secondary to another disease entity and can range from affecting only one organ to being a multiorgan systemic disease. Primary vasculitides frequently have some pulmonary manifestations, which may be part of the initial presentation. Discovery of pulmonary artery aneurysms, multiple pulmonary infarcts, and diffuse alveolar hemorrhage should always raise the question of an undiagnosed vasculitis. Takayasu arteritis, also called aortic arch syndrome, middle aortic syndrome, occlusive thromboaortopathy, and nonspecific aortoarteritis, requires a high index of suspicion for an early accurate diagnosis. Giant cell arteritis (GCA) receives its name from its typical histologic pattern. Classically a medium- and large-vessel vasculitis, GCA can affect all vessels of the body but has a predilection for extracranial branches of the carotid artery. Behcet’s disease is a systemic idiopathic vasculitis with recurrent episodes of acute inflammation in multiple organ systems. It is classified as a variable-vessel vasculitis as it can affect small, medium, and large vessels, both arteries and veins. Classically a medium-vessel vasculitis, polyarteritis nodosa is a systemic necrotizing vasculitis that can also affect small vessels. Necrotizing sarcoid granulomatosis is an exceedingly rare type of vasculitis that is usually confined to the lungs and is a diagnosis of exclusion. It is characterized by sarcoid-like granulomas, granulomatous vasculitis, and a variable amount of necrosis. Kawasaki Disease has been reported globally, but there’s a strong geographic and ethnic predominance. The highest incidence is in Japan. The best-established prognostic factor for the most feared complication in those with Kawasaki, coronary artery aneurysms, is age of onset. Isolated pauci-immune capillaritis is a small-vessel vasculitis that is localized to the lung with no other clinical or serologic markers of a systemic disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Adams TN, et al. Pulmonary manifestations of large, medium, and variable vessel vasculitis. Respir Med. 2018;145:182–91.

    Article  PubMed  Google Scholar 

  2. Terao C. History of Takayasu arteritis and Dr. Mikito Takayasu. Int J Rheum Dis. 2014;17(8):931–5.

    Article  PubMed  Google Scholar 

  3. Lazzarin P, et al. Takayasu’s arteritis. A concise review and some observations on a putative case reported by Giovanni Battista Morgagni (1761). Reumatismo. 2005;57(4):305–13.

    CAS  PubMed  Google Scholar 

  4. Numano F. The story of Takayasu arteritis. Rheumatology. 2002;41(1):103–6.

    Article  CAS  PubMed  Google Scholar 

  5. Zaldivar Villon MLF, de la Rocha JAL, Espinoza LR. Takayasu arteritis: recent developments. Curr Rheumatol Rep. 2019;21(9):45.

    Article  PubMed  Google Scholar 

  6. Hall S, et al. Takayasu arteritis. A study of 32 North American patients. Medicine. 1985;64(2):89–99.

    Article  CAS  PubMed  Google Scholar 

  7. Takamura C, et al. New human leukocyte antigen risk allele in Japanese patients with Takayasu arteritis. Circ J. 2012;76(7):1697–702.

    Article  CAS  PubMed  Google Scholar 

  8. Toshihiko N. Current status of large and small vessel vasculitis in Japan. Int J Cardiol. 1996;54(Suppl):S91–8.

    Article  PubMed  Google Scholar 

  9. El Reshaid K, et al. Takayasu’s arteritis in Kuwait. J Trop Med Hyg. 1995;98(5):299–305.

    PubMed  Google Scholar 

  10. Gudbrandsson B, et al. Prevalence, incidence, and disease characteristics of Takayasu arteritis by ethnic background: data from a large, population-based cohort resident in Southern Norway. Arthritis Care Res. 2017;69(2):278–85.

    Article  Google Scholar 

  11. Sanchez-Alvarez C, et al. Demographic, clinical, and radiologic characteristics of a cohort of patients with Takayasu arteritis. Am J Med. 2019;132(5):647–51.

    Article  PubMed  Google Scholar 

  12. Terao C. Revisited HLA and non-HLA genetics of Takayasu arteritis–where are we? J Hum Genet. 2016;61(1):27–32.

    Article  CAS  PubMed  Google Scholar 

  13. Mirault T, Guillet H, Messas E. Presse Med. 2017;46(7-8):189–96.

    Article  Google Scholar 

  14. Espinoza JL, Ai S, Matsumura I. New insights on the pathogenesis of Takayasu arteritis: revisiting the microbial theory. Pathogens. 2018;7(3):73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Weyand CM, et al. Cytokines, growth factors and proteases in medium and large vessel vasculitis. Clin Immunol. 2019;206:33–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Tamura N, et al. Profiles of serum cytokine levels in Takayasu arteritis patients: potential utility as biomarkers for monitoring disease activity. J Cardiol. 2017;70(3):278–85.

    Article  PubMed  Google Scholar 

  17. Kerr GS, et al. Takayasu arteritis. Ann Intern Med. 1994;120(11):919–29.

    Article  CAS  PubMed  Google Scholar 

  18. Nakao K, et al. Takayasu’s arteritis. Clinical report of eighty-four cases and immunological studies of seven cases. Circulation. 1967;35(6):1141–55.

    Article  CAS  PubMed  Google Scholar 

  19. Kwon OC, et al. Extravascular manifestations of Takayasu arteritis: focusing on the features shared with spondyloarthritis. Arthritis Res Ther. 2018;20(1):142.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Tomelleri A, et al. Gender differences in clinical presentation and vascular pattern in patients with Takayasu arteritis. Scand J Rheumatol. 2019;48(6):482–90.

    Article  CAS  PubMed  Google Scholar 

  21. Watanabe Y, Miyata T, Tanemoto K. Current clinical features of new patients with Takayasu arteritis observed from cross-country research in Japan: age and sex specificity. Circulation. 2015;132(18):1701–9.

    Article  PubMed  Google Scholar 

  22. Sari A, et al. Pulmonary hypertension in Takayasu arteritis. Int J Rheum Dis. 2018;21(8):1634–9.

    Article  PubMed  Google Scholar 

  23. Galiè N, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46(4):903–75.

    Article  PubMed  Google Scholar 

  24. Jiang W, et al. Echocardiographic characteristics of pulmonary artery involvement in Takayasu arteritis. Echocardiography. 2017;34(3):340–7.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990;33(8):1129–34.

    Article  CAS  PubMed  Google Scholar 

  26. Sharma BK, et al. Diagnostic criteria for Takayasu arteritis. Int J Cardiol. 1996;54(Suppl):141–7.

    Article  Google Scholar 

  27. Aydin SZ, Direskeneli H, Merkel PA. Assessment of disease activity in large-vessel vasculitis: results of an international delphi exercise. J Rheumatol. 2017;44(12):1928–32.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Li J, et al. Tofacitinib in patients with refractory Takayasu’s arteritis. Rheumatology. 2020;59(11):95–8.

    Article  CAS  Google Scholar 

  29. Kim H, Barra L. Ischemic complications in Takayasu’s arteritis: a meta-analysis. Semin Arthritis Rheum. 2018;47(6):900–6.

    Article  PubMed  Google Scholar 

  30. Kim ESH, Beckman J. Takayasu arteritis: challenges in diagnosis and management. Heart. 2018;104(7):558–65.

    Article  CAS  PubMed  Google Scholar 

  31. Saadoun D, et al. Retrospective analysis of surgery versus endovascular intervention in Takayasu arteritis: a multicenter experience. Circulation. 2012;125(6):813–9.

    Article  CAS  PubMed  Google Scholar 

  32. Ham SW, et al. Disease progression after initial surgical intervention for Takayasu arteritis. J Vasc Surg. 2011;54(5):1345–51.

    Article  PubMed  Google Scholar 

  33. de Souza AW, et al. Antiplatelet therapy for the prevention of arterial ischemic events in Takayasu arteritis. Circ J. 2010;74(6):1236–41.

    Article  PubMed  Google Scholar 

  34. Park MC, et al. Post-interventional immunosuppressive treatment and vascular restenosis in Takayasu’s arteritis. Rheumatology. 2006;45(5):600–5.

    Article  CAS  PubMed  Google Scholar 

  35. Gomułka K, et al. Horton’s disease: still an important medical problem in elderly patients: a review and case report. Postepy Dermatol Alergol. 2017;34(5):510–3.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Nesher G. The diagnosis and classification of giant cell arteritis. J Autoimmun. 2014;48-49:73–5.

    Article  CAS  PubMed  Google Scholar 

  37. Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58(1):26–35.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Buttgereit F, et al. Polymyalgia rheumatica and giant cell arteritis: a systematic review. JAMA. 2016;315(22):2442–58.

    Article  CAS  PubMed  Google Scholar 

  39. Carmona FD, et al. A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility. Am J Hum Genet. 2015;96(4):565–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Duhaut P, Bosshard S, Ducroix JP. Is giant cell arteritis an infectious disease? Biological and epidemiological evidence. Presse Med. 2004;33(19):1403–8.

    Article  PubMed  Google Scholar 

  41. Weyand CM, Goronzy JJ. Clinical practice. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med. 2014;371(1):50–7.

    Article  PubMed  PubMed Central  Google Scholar 

  42. de Boysson H, et al. Large-vessel involvement and aortic dilation in giant-cell arteritis. A multicenter study of 549 patients. Autoimmun Rev. 2018;17(4):391–8.

    Article  PubMed  Google Scholar 

  43. Noumegni SR, et al. Temporal artery ultrasound to diagnose giant cell arteritis: a practical guide. Ultrasound Med Biol. 2021;47(2):201–13.

    Article  PubMed  Google Scholar 

  44. Kaushik M, Ponte C, Mollan SP. Current advances in giant cell arteritis. Curr Opin Neurol. 2021;34(1):133–41.

    Article  CAS  PubMed  Google Scholar 

  45. Okubo S, et al. Idiopathic isolated pulmonary arteritis with chronic cor pulmonale. Chest. 1988;94(3):665–6.

    Article  CAS  PubMed  Google Scholar 

  46. Larson TS, et al. Respiratory tract symptoms as a clue to giant cell arteritis. Ann Intern Med. 1984;101(5):594–7.

    Article  CAS  PubMed  Google Scholar 

  47. Zenone T, Puget M. Dry cough is a frequent manifestation of giant cell arteritis. Rheumatol Int. 2013;33(8):2165–8.

    Article  PubMed  Google Scholar 

  48. Kramer MR, et al. Pulmonary manifestations of temporal arteritis. Eur J Respir Dis. 1987;71(5):430–3.

    CAS  PubMed  Google Scholar 

  49. Konishi C, et al. Interstitial lung disease as an initial manifestation of giant cell arteritis. Intern Med. 2017;56(19):2633–7.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Wagenaar SS, et al. Isolated granulomatous giant cell vasculitis of the pulmonary elastic arteries. Arch Pathol Lab Med. 1986;110(10):962–4.

    CAS  PubMed  Google Scholar 

  51. Oh LJ, et al. Value of temporal artery biopsy length in diagnosing giant cell arteritis. ANZ J Surg. 2018;88(3):191–5.

    Article  PubMed  Google Scholar 

  52. Narváez J, et al. Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis. Semin Arthritis Rheum. 2007;37(1):13–9.

    Article  PubMed  Google Scholar 

  53. Hunder GG, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33(8):1122–8.

    Article  CAS  PubMed  Google Scholar 

  54. Kermani TA, et al. Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis. Semin Arthritis Rheum. 2012;41(6):866–71.

    Article  CAS  PubMed  Google Scholar 

  55. Schmidt WA, et al. Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med. 1997;337(19):1336–42.

    Article  CAS  PubMed  Google Scholar 

  56. Brack A, et al. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum. 1999;42(2):311–7.

    Article  CAS  PubMed  Google Scholar 

  57. Blockmans D, et al. Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch. Am J Med. 2000;108(3):246–9.

    Article  CAS  PubMed  Google Scholar 

  58. Mainbourg S, et al. Prevalence of giant cell arteritis relapse in patients treated with glucocorticoids: a meta-analysis. Arthritis Care Res. 2020;72(6):838–49.

    Article  CAS  Google Scholar 

  59. Mahr AD, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 2007;56(8):2789–97.

    Article  CAS  PubMed  Google Scholar 

  60. Villiger PM, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387(10031):1921–7.

    Article  CAS  PubMed  Google Scholar 

  61. Stone JH, Klearman M, Collinson N. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(15):1494–5.

    PubMed  Google Scholar 

  62. Kermani TA, et al. Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis. Ann Rheum Dis. 2013;72(12):1989–94.

    Article  PubMed  Google Scholar 

  63. Tan SY, Poole PS. Hulusi Behçet (1889-1948): passion for dermatology. Singap Med J. 2016;57(7):408–9.

    Article  Google Scholar 

  64. Feigenbaum A. Description of Behçet’s syndrome in the Hippocratic third book of endemic diseases. Br J Ophthalmol. 1956;40(6):355–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Davatchi F, et al. Behcet’s disease: epidemiology, clinical manifestations, and diagnosis. Expert Rev Clin Immunol. 2017;13(1):57–65.

    Article  CAS  PubMed  Google Scholar 

  66. Emmi G, et al. Vascular Behçet’s syndrome: an update. Intern Emerg Med. 2019;14(5):645–52.

    Article  PubMed  Google Scholar 

  67. Lally L, Spiera RF. Pulmonary vasculitis. Rheum Dis Clin N Am. 2015;41(2):315–31.

    Article  Google Scholar 

  68. Davatchi F, et al. Behcet’s disease in Iran: analysis of 6500 cases. Int J Rheum Dis. 2010;13(4):367–73.

    Article  PubMed  Google Scholar 

  69. Borhani Haghighi A, Pourmand R, Nikseresht AR. Neuro-Behçet disease. A review. Neurologist. 2005;11(2):80–9.

    Article  PubMed  Google Scholar 

  70. The International Criteria for Behçet’s Disease (ICBD). A collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28(3):338–47.

    Article  Google Scholar 

  71. Tascilar K, et al. Vascular involvement in Behçet’s syndrome: a retrospective analysis of associations and the time course. Rheumatology. 2014;53(11):2018–22.

    Article  CAS  PubMed  Google Scholar 

  72. Seyahi E, Yazici H. Behçet’s syndrome: pulmonary vascular disease. Curr Opin Rheumatol. 2015;27(1):18–23.

    Article  PubMed  Google Scholar 

  73. Khalid U, Saleem T. Hughes-Stovin syndrome. Orphanet J Rare Dis. 2011;6:15.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Hughes JP, Stovin PG. Segmental pulmonary artery aneurysms with peripheral venous thrombosis. Br J Dis Chest. 1959;53(1):19–27.

    Article  CAS  PubMed  Google Scholar 

  75. Seyahi E, et al. Pulmonary artery involvement and associated lung disease in Behçet disease: a series of 47 patients. Medicine. 2012;91(1):35–48.

    Article  PubMed  Google Scholar 

  76. Edrees A, et al. Pulmonary manifestations in a group of patients with Behcet's disease. Int J Rheum Dis. 2017;20(2):269–75.

    Article  PubMed  Google Scholar 

  77. Hamuryudan V, et al. Pulmonary arterial aneurysms in Behçet’s syndrome: a report of 24 cases. Br J Rheumatol. 1994;33(1):48–51.

    Article  CAS  PubMed  Google Scholar 

  78. Abadoğlu O, et al. Behçet’s disease with pulmonary involvement, superior vena cava syndrome, chyloptysis and chylous ascites. Respir Med. 1996;90(7):429–31.

    Article  PubMed  Google Scholar 

  79. Kim HK, et al. Behçet disease complicated by diffuse alveolar damage. J Thorac Imaging. 2005;20(1):55–7.

    Article  PubMed  Google Scholar 

  80. Ning-Sheng L, Chun-Liang L, Ray-Sheng L. Bronchiolitis obliterans organizing pneumonia in a patient with Behçet’s disease. Scand J Rheumatol. 2004;33(6):437–40.

    Article  CAS  PubMed  Google Scholar 

  81. Ahonen AV, et al. Obstructive lung disease in Behcet’s syndrome. Scand J Respir Dis. 1978;59(1):44–50.

    CAS  PubMed  Google Scholar 

  82. Tunaci A, Berkmen YM, Gökmen E. Thoracic involvement in Behçet’s disease: pathologic, clinical, and imaging features. AJR Am J Roentgenol. 1995;164(1):51–6.

    Article  CAS  PubMed  Google Scholar 

  83. Davatchi F, et al. The saga of diagnostic/classification criteria in Behcet’s disease. Int J Rheum Dis. 2015;18(6):594–605.

    Article  PubMed  Google Scholar 

  84. Hatemi G, et al. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis. 2018;77(6):808–18.

    PubMed  Google Scholar 

  85. Desbois AC, et al. Immunosuppressants reduce venous thrombosis relapse in Behçet’s disease. Arthritis Rheum. 2012;64(8):2753–60.

    Article  CAS  PubMed  Google Scholar 

  86. Baki K, et al. Behcet’s disease with life-threatening haemoptoe and pulmonary aneurysms: complete remission after infliximab treatment. Ann Rheum Dis. 2006;65(11):1531–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Hosaka A, et al. Long-term outcome after surgical treatment of arterial lesions in Behçet disease. J Vasc Surg. 2005;42(1):116–21.

    Article  PubMed  Google Scholar 

  88. Park KD, et al. Clinical study on death in Behçet’s disease. J Korean Med Sci. 1993;8(4):241–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Saadoun D, et al. Mortality in Behçet’s disease. Arthritis Rheum. 2010;62(9):2806–12.

    Article  CAS  PubMed  Google Scholar 

  90. Hamuryudan V, et al. Pulmonary artery aneurysms in Behçet syndrome. Am J Med. 2004;117(11):867–70.

    Article  PubMed  Google Scholar 

  91. Guillevin L, et al. Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Medicine. 1995;74(5):238–53.

    Article  CAS  PubMed  Google Scholar 

  92. Ramos-Casals M, et al. Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry). J Rheumatol. 2009;36(7):1442–8.

    Article  PubMed  Google Scholar 

  93. Rodrigo D, Perera R, de Silva J. Classic polyarteritis nodosa associated with hepatitis C virus infection: a case report. J Med Case Rep. 2012;6:305.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Zignego AL, et al. International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. Autoimmun Rev. 2017;16(5):523–41.

    Article  PubMed  Google Scholar 

  95. Hasler P, Kistler H, Gerber H. Vasculitides in hairy cell leukemia. Semin Arthritis Rheum. 1995;25(2):134–42.

    Article  CAS  PubMed  Google Scholar 

  96. Guillevin L, et al. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine. 2005;84(5):313–22.

    Article  PubMed  Google Scholar 

  97. Pagnoux C, et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum. 2010;62(2):616–26.

    Article  PubMed  Google Scholar 

  98. Matteoda MA, et al. Cutaneous polyarteritis nodosa. An Bras Dermatol. 2015;90(3 Suppl 1):188–90.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Chasset F, Francès C. Cutaneous manifestations of medium- and large-vessel vasculitis. Clin Rev Allergy Immunol. 2017;53(3):452–68.

    Article  CAS  PubMed  Google Scholar 

  100. Balow JE. Renal vasculitis. Kidney Int. 1985;27(6):954–64.

    Article  CAS  PubMed  Google Scholar 

  101. Menon Y, et al. Pulmonary involvement in hepatitis B-related polyarteritis nodosa. Chest. 2002;122(4):1497–8.

    Article  PubMed  Google Scholar 

  102. Matsumoto T, et al. The lung in polyarteritis nodosa: a pathologic study of 10 cases. Hum Pathol. 1993;24(7):717–24.

    Article  CAS  PubMed  Google Scholar 

  103. Robinson BW, Sterrett G. Bronchiolitis obliterans associated with polyarteritis nodosa. Chest. 1992;102(1):309–11.

    Article  CAS  PubMed  Google Scholar 

  104. Le Thi Huong DL, et al. Pulmonary artery stenosis and periarteritis nodosa. Scand J Rheumatol. 1996;25(4):266–7.

    Article  PubMed  Google Scholar 

  105. Lee YJ, et al. A case of systemic polyarteritis nodosa involving bronchial artery. Sarcoidosis Vasc Diffuse Lung Dis. 2010;27(2):164–8.

    CAS  PubMed  Google Scholar 

  106. Lightfoot RW Jr, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum. 1990;33(8):1088–93.

    Article  PubMed  Google Scholar 

  107. Schmidt WA. Use of imaging studies in the diagnosis of vasculitis. Curr Rheumatol Rep. 2004;6(3):203–11.

    Article  PubMed  Google Scholar 

  108. Ribi C, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: a prospective randomized study of one hundred twenty-four patients. Arthritis Rheum. 2010;62(4):1186–97.

    Article  PubMed  Google Scholar 

  109. Guillevin L, et al. The five-factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine. 2011;90(1):19–27.

    Article  PubMed  Google Scholar 

  110. Tasleem A, et al. A rare case study about necrotizing granulomatous sarcoidosis. Cureus. 2020;12(9):e10220.

    PubMed  PubMed Central  Google Scholar 

  111. Pourabdollah M, et al. Necrotizing sarcoid granulomatosis with pneumothorax. Case Rep Med. 2019;2019:4648720.

    Article  PubMed  PubMed Central  Google Scholar 

  112. Liebow AA. The J. Burns Amberson lecture–pulmonary angiitis and granulomatosis. Am Rev Respir Dis. 1973;108(1):1–18.

    CAS  PubMed  Google Scholar 

  113. Rosen Y. Four decades of necrotizing sarcoid granulomatosis: what do we know now? Arch Pathol Lab Med. 2015;139(2):252–62.

    Article  PubMed  Google Scholar 

  114. Le Gall F, et al. Necrotizing sarcoid granulomatosis with and without extrapulmonary involvement. Pathol Res Pract. 1996;192(3):306–13; discussion 314.

    Article  PubMed  Google Scholar 

  115. Yeboah J, et al. Necrotizing sarcoid granulomatosis. Curr Opin Pulm Med. 2012;18(5):493–8.

    Article  CAS  PubMed  Google Scholar 

  116. Abid H, Siddiqui N. A rare case of necrotizing sarcoid granulomatosis involving liver. Cureus. 2019;11(8):e5366.

    PubMed  PubMed Central  Google Scholar 

  117. Dykhuizen RS, et al. Necrotizing sarcoid granulomatosis with extrapulmonary involvement. Eur Respir J. 1997;10(1):245–7.

    Article  CAS  PubMed  Google Scholar 

  118. Fisher MR, Christ ML, Bernstein JR. Necrotizing sarcoid-like granulomatosis: radiologic-pathologic correlation. J Can Assoc Radiol. 1984;35(3):313–5.

    CAS  PubMed  Google Scholar 

  119. Niimi H, Hartman TE, Müller NL. Necrotizing sarcoid granulomatosis: computed tomography and pathologic findings. J Comput Assist Tomogr. 1995;19(6):920–3.

    Article  CAS  PubMed  Google Scholar 

  120. Shibata T, et al. Necrotizing sarcoid granulomatosis with natural resolution after a surgical lung biopsy. Intern Med. 2018;57(11):1625–9.

    Article  PubMed  PubMed Central  Google Scholar 

  121. Quaden C, et al. Necrotising sarcoid granulomatosis: clinical, functional, endoscopical and radiographical evaluations. Eur Respir J. 2005;26(5):778–85.

    Article  CAS  PubMed  Google Scholar 

  122. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi. 1967;16(3):178–222.

    CAS  PubMed  Google Scholar 

  123. Rife E, Gedalia A. Kawasaki disease: an update. Curr Rheumatol Rep. 2020;22(10):75.

    Article  PubMed  PubMed Central  Google Scholar 

  124. Soni PR, Noval Rivas M, Arditi M. A comprehensive update on Kawasaki disease vasculitis and myocarditis. Curr Rheumatol Rep. 2020;22(2):6.

    Article  PubMed  Google Scholar 

  125. Makino N, et al. Descriptive epidemiology of Kawasaki disease in Japan, 2011-2012: from the results of the 22nd nationwide survey. J Epidemiol. 2015;25(3):239–45.

    Article  PubMed  Google Scholar 

  126. Makino N, et al. Nationwide epidemiologic survey of Kawasaki disease in Japan, 2015-2016. Pediatr Int. 2019;61(4):397–403.

    Article  PubMed  Google Scholar 

  127. Holman RC, et al. Hospitalizations for Kawasaki syndrome among children in the United States, 1997-2007. Pediatr Infect Dis J. 2010;29(6):483–8.

    Article  PubMed  Google Scholar 

  128. Rodó X, et al. Tropospheric winds from northeastern China carry the etiologic agent of Kawasaki disease from its source to Japan. Proc Natl Acad Sci U S A. 2014;111(22):7952–7.

    Article  PubMed  PubMed Central  Google Scholar 

  129. Rodó X, et al. Revisiting the role of environmental and climate factors on the epidemiology of Kawasaki disease. Ann N Y Acad Sci. 2016;1382(1):84–98.

    Article  PubMed  Google Scholar 

  130. Burns JC, et al. Seasonality and temporal clustering of Kawasaki syndrome. Epidemiology. 2005;16(2):220–5.

    Article  PubMed  PubMed Central  Google Scholar 

  131. McMurray JC, et al. Multisystem inflammatory syndrome in children (MIS-C), a post-viral myocarditis and systemic vasculitis-a critical review of its pathogenesis and treatment. Front Pediatr. 2020;8:626182.

    Article  PubMed  PubMed Central  Google Scholar 

  132. Uehara R, et al. Kawasaki disease in parents and children. Acta Paediatr. 2003;92(6):694–7.

    Article  CAS  PubMed  Google Scholar 

  133. Uehara R, et al. Clinical features of patients with Kawasaki disease whose parents had the same disease. Arch Pediatr Adolesc Med. 2004;158(12):1166–9.

    Article  PubMed  Google Scholar 

  134. Dergun M, et al. Familial occurrence of Kawasaki syndrome in North America. Arch Pediatr Adolesc Med. 2005;159(9):876–81.

    Article  PubMed  PubMed Central  Google Scholar 

  135. Franco A, et al. Memory T-cells and characterization of peripheral T-cell clones in acute Kawasaki disease. Autoimmunity. 2010;43(4):317–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  136. Rowley AH, et al. IgA plasma cell infiltration of proximal respiratory tract, pancreas, kidney, and coronary artery in acute Kawasaki disease. J Infect Dis. 2000;182(4):1183–91.

    Article  CAS  PubMed  Google Scholar 

  137. Uehara R, Belay ED. Epidemiology of Kawasaki disease in Asia, Europe, and the United States. J Epidemiol. 2012;22(2):79–85.

    Article  PubMed  PubMed Central  Google Scholar 

  138. Singh S, et al. Pulmonary presentation of Kawasaki disease-A diagnostic challenge. Pediatr Pulmonol. 2018;53(1):103–7.

    Article  PubMed  Google Scholar 

  139. Leahy TR, Cohen E, Allen UD. Incomplete Kawasaki disease associated with complicated Streptococcus pyogenes pneumonia: a case report. Can J Infect Dis Med Microbiol. 2012;23(3):137–9.

    Article  PubMed  PubMed Central  Google Scholar 

  140. Vaidya PC, et al. Pulmonary presentation of Kawasaki disease: an unusual occurrence. Int J Rheum Dis. 2017;20(12):2227–9.

    Article  PubMed  Google Scholar 

  141. Uziel Y, et al. “Unresolving pneumonia” as the main manifestation of atypical Kawasaki disease. Arch Dis Child. 2003;88(10):940–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  142. De Maddi F, et al. Lung parenchymal consolidation as an uncommon presentation and cause of delayed diagnosis in atypical Kawasaki syndrome. Rheumatol Int. 2009;29(11):1373–6.

    Article  PubMed  Google Scholar 

  143. Umezawa T, et al. Chest X-ray findings in the acute phase of Kawasaki disease. Pediatr Radiol. 1989;20(1-2):48–51.

    Article  CAS  PubMed  Google Scholar 

  144. McCrindle BW, et al. Diagnosis, treatment, and long-term management of kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135(17):e927–99.

    Article  PubMed  Google Scholar 

  145. Council on Cardiovascular Disease in the Young Committee on Rheumatic Fever Endocarditis and Kawasaki Disease American Heart Association. Diagnostic guidelines for Kawasaki disease. Circulation. 2001;103(2):335–6.

    Article  Google Scholar 

  146. de Graeff N, et al. European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease - the SHARE initiative. Rheumatology. 2019;58(4):672–82.

    Article  PubMed  Google Scholar 

  147. Ha KS, et al. Incomplete clinical manifestation as a risk factor for coronary artery abnormalities in Kawasaki disease: a meta-analysis. Eur J Pediatr. 2013;172(3):343–9.

    Article  PubMed  Google Scholar 

  148. Yi L, et al. Elevated levels of platelet activating factor and its acetylhydrolase indicate high risk of Kawasaki disease. J Interf Cytokine Res. 2020;40(3):159–67.

    Article  CAS  Google Scholar 

  149. Cameron SA, et al. Coronary artery aneurysms are more severe in infants than in older children with Kawasaki disease. Arch Dis Child. 2019;104(5):451–5.

    Article  PubMed  Google Scholar 

  150. Kavey RE, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation. 2006;114(24):2710–38.

    Article  PubMed  Google Scholar 

  151. Beiser AS, et al. A predictive instrument for coronary artery aneurysms in Kawasaki disease. US Multicenter Kawasaki Disease Study Group. Am J Cardiol. 1998;81(9):1116–20.

    Article  CAS  PubMed  Google Scholar 

  152. Salgado AP, et al. High risk of coronary artery aneurysms in infants younger than 6 months of age with Kawasaki disease. J Pediatr. 2017;185:112–6.

    Article  PubMed  PubMed Central  Google Scholar 

  153. Hayasaka S, et al. Analyses of fatal cases of Kawasaki disease in Japan using vital statistical data over 27 years. J Epidemiol. 2003;13(5):246–50.

    Article  PubMed  Google Scholar 

  154. Nierman DM, et al. A patient with antineutrophil cytoplasmic antibody-negative pulmonary capillaritis and circulating primed neutrophils. Arthritis Rheum. 1995;38(12):1855–8.

    Article  CAS  PubMed  Google Scholar 

  155. Jennings CA, et al. Diffuse alveolar hemorrhage with underlying isolated, pauciimmune pulmonary capillaritis. Am J Respir Crit Care Med. 1997;155(3):1101–9.

    Article  CAS  PubMed  Google Scholar 

  156. Mehrotra AK, et al. Isolated pauci-immune pulmonary capillaritis. Lung. 2015;32(1):56–9.

    Google Scholar 

  157. Lara AR, Schwarz MI. Diffuse alveolar hemorrhage. Chest. 2010;137(5):1164–71.

    Article  PubMed  Google Scholar 

  158. Jiang C, et al. Rapidly progressive course of pauci-immune pulmonary capillaritis in a 70-year-old Asian male refractory to immunosuppression and plasma exchange. BMJ Case Rep. 2020;13(3):e233577.

    Article  PubMed  PubMed Central  Google Scholar 

  159. Brown KK. Pulmonary vasculitis. Proc Am Thorac Soc. 2006;3(1):48–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  160. Travis WD, et al. A clinicopathologic study of 34 cases of diffuse pulmonary hemorrhage with lung biopsy confirmation. Am J Surg Pathol. 1990;14(12):1112–25.

    Article  CAS  PubMed  Google Scholar 

  161. Flanagan F, Glackin L, Slattery DM. Successful treatment of idiopathic pulmonary capillaritis with intravenous cyclophosphamide. Pediatr Pulmonol. 2013;48(3):303–5.

    Article  PubMed  Google Scholar 

  162. Lewinter KE, et al. Successful induction treatment with rituximab of isolated pauci-immune pulmonary capillaritis presenting as diffuse alveolar hemorrhage in a pediatric patient. Chest. 2020;158(5):e225–7.

    Article  CAS  PubMed  Google Scholar 

  163. Stone JH, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  164. Lutalo PM, D’Cruz DP. Diagnosis and classification of granulomatosis with polyangiitis (aka Wegener’s granulomatosis). J Autoimmun. 2014;48-49:94–8.

    Article  CAS  PubMed  Google Scholar 

  165. Mohammad AJ, et al. Incidence and survival rates in Wegener’s granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology. 2009;48(12):1560–5.

    Article  PubMed  Google Scholar 

  166. Watts RA, Lane S, Scott DG. What is known about the epidemiology of the vasculitides? Best Pract Res Clin Rheumatol. 2005;19(2):191–207.

    Article  PubMed  Google Scholar 

  167. Zycinska K, et al. Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement. Eur J Med Res. 2009;14(Suppl 4):265–7.

    Article  PubMed  PubMed Central  Google Scholar 

  168. Gómez-Gómez A, et al. Pulmonary manifestations of granulomatosis with polyangiitis. Reumatol Clin. 2014;10(5):288–93.

    Article  PubMed  Google Scholar 

  169. Hong Y, et al. Anti-neutrophil cytoplasmic antibodies stimulate release of neutrophil microparticles. J Am Soc Nephrol. 2012;23(1):49–62.

    Article  CAS  PubMed  Google Scholar 

  170. Kraaij T, et al. Excessive neutrophil extracellular trap formation in ANCA-associated vasculitis is independent of ANCA. Kidney Int. 2018;94(1):139–49.

    Article  CAS  PubMed  Google Scholar 

  171. Abdulahad WH, et al. Functional defect of circulating regulatory CD4+ T cells in patients with Wegener’s granulomatosis in remission. Arthritis Rheum. 2007;56(6):2080–91.

    Article  CAS  PubMed  Google Scholar 

  172. Unizony S, et al. Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2015;67(2):535–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  173. Kallenberg CG. Key advances in the clinical approach to ANCA-associated vasculitis. Nat Rev Rheumatol. 2014;10(8):484–93.

    Article  CAS  PubMed  Google Scholar 

  174. Jennette JC, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1–11.

    Article  CAS  PubMed  Google Scholar 

  175. Brons RH, et al. Detection of immune deposits in skin lesions of patients with Wegener’s granulomatosis. Ann Rheum Dis. 2001;60(12):1097–102.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  176. Muller K, Lin JH. Orbital granulomatosis with polyangiitis (Wegener granulomatosis): clinical and pathologic findings. Arch Pathol Lab Med. 2014;138(8):1110–4.

    Article  PubMed  PubMed Central  Google Scholar 

  177. Martinez Del Pero M, et al. Long-term damage to the ENT system in Wegener’s granulomatosis. Eur Arch Otorhinolaryngol. 2011;268(5):733–9.

    Article  PubMed  Google Scholar 

  178. Fasunla JA, et al. Evaluation of smell and taste in patients with Wegener’s granulomatosis. Eur Arch Otorhinolaryngol. 2012;269(1):179–86.

    Article  PubMed  Google Scholar 

  179. Lee KS, et al. Thoracic manifestation of Wegener’s granulomatosis: CT findings in 30 patients. Eur Radiol. 2003;13(1):43–51.

    Article  PubMed  Google Scholar 

  180. Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. Lancet. 2006;368(9533):404–18.

    Article  CAS  PubMed  Google Scholar 

  181. Niles JL, et al. The syndrome of lung hemorrhage and nephritis is usually an ANCA-associated condition. Arch Intern Med. 1996;156(4):440–5.

    Article  CAS  PubMed  Google Scholar 

  182. Luqmani RA, et al. Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis. QJM. 1994;87(11):671–8.

    CAS  PubMed  Google Scholar 

  183. Mukhtyar C, et al. Modification and validation of the Birmingham vasculitis activity score (version 3). Ann Rheum Dis. 2009;68(12):1827–32.

    Article  CAS  PubMed  Google Scholar 

  184. Cordier JF, Valeyre D, Guillevin L, Loire R, Brechot JM. Pulmonary Wegener’s granulomatosis. A clinical and imaging study of 77 cases. Chest. 1990;97:906–12.

    Article  CAS  PubMed  Google Scholar 

  185. Schubert F, Muhle C, Schnabel A, et al. High-resolution CT (HRCT) of the lung in Wegener’s granulomatosis. Röfo. 1994;161:19–24.

    CAS  PubMed  Google Scholar 

  186. Guneyli S, Ceylan N, Bayraktaroglu S, et al. Imaging findings of pulmonary granulomatosis with polyangiitis (Wegener’s granulomatosis): lesions invading the pulmonary fissure, pleura or diaphragm mimicking malignancy. Wien Klin Wochenschr. 2016;128:809–15.

    Article  PubMed  Google Scholar 

  187. Martinez F, Chung JH, Digumarthy SR, et al. Common and uncommon manifestations of Wegener granulomatosis at chest CT: radiologic-pathologic correlation. Radiographics. 2012;32:51–69.

    Article  PubMed  Google Scholar 

  188. Lohrmann C, Uhl M, Kotter E, Burger D, Ghanem N, Langer M. Pulmonary manifestations of Wegener granulomatosis: CT findings in 57 patients and a review of the literature. Eur J Radiol. 2005;53:471–7.

    Article  PubMed  Google Scholar 

  189. Pretorius ES, Stone JH, Hellman DB, Fishman EK. Wegener’s granulomatosis: CT evolution of pulmonary parenchymal findings in treated disease. Crit Rev Comput Tomogr. 2004;45:67–85.

    Article  PubMed  Google Scholar 

  190. Reuter M, Schnabel A, Wesner F, et al. Pulmonary Wegener’s granulomatosis: correlation between high-resolution CT findings and clinical scoring of disease activity. Chest. 1998;114:500–6.

    Article  CAS  PubMed  Google Scholar 

  191. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983;98:76–85.

    Article  CAS  PubMed  Google Scholar 

  192. Maskell GF, Lockwood CM, Flower CD. Computed tomography of the lung in Wegener’s granulomatosis. Clin Radiol. 1993;48:377–80.

    Article  CAS  PubMed  Google Scholar 

  193. Aberle DR, Gamsu G, Lynch D. Thoracic manifestations of Wegener granulomatosis: diagnosis and course. Radiology. 1990;174:703–9.

    Article  CAS  PubMed  Google Scholar 

  194. Russell B, Mohan S, Chahal R, Carette S, Pagnoux C. Prognostic significance of cavitary lung nodules in granulomatosis with polyangiitis (Wegener’s): a clinical imaging study of 225 patients. Arthritis Care Res. 2018;70:1082–9.

    Article  Google Scholar 

  195. Gorospe L, Ajuria-Illarramendi O, de la Puente-Bujidos C, et al. PET/CT findings of granulomatosis with polyangiitis presenting as a solitary pulmonary nodule and mimicking lung cancer. J Clin Rheumatol. 2020;26:e122–e3.

    Article  PubMed  Google Scholar 

  196. Marchiori E, Zanetti G, Meirelles GS, Escuissato DL, Souza AS Jr, Hochhegger B. The reversed halo sign on high-resolution CT in infectious and noninfectious pulmonary diseases. AJR Am J Roentgenol. 2011;197:W69–75.

    Article  PubMed  Google Scholar 

  197. Pinto PS, The CT. Halo sign. Radiology. 2004;230:109–10.

    Article  PubMed  Google Scholar 

  198. Lee KS, Kim TS, Fujimoto K, et al. Thoracic manifestation of Wegener’s granulomatosis: CT findings in 30 patients. Eur Radiol. 2003;13:43–51.

    Article  PubMed  Google Scholar 

  199. Hansell DM. Small-vessel diseases of the lung: CT-pathologic correlates. Radiology. 2002;225:639–53.

    Article  PubMed  Google Scholar 

  200. Attali P, Begum R, Ban Romdhane H, Valeyre D, Guillevin L, Brauner MW. Pulmonary Wegener’s granulomatosis: changes at follow-up CT. Eur Radiol. 1998;8:1009–113.

    Article  CAS  PubMed  Google Scholar 

  201. Kuhlman JE, Hruban RH, Fishman EK. Wegener granulomatosis: CT features of parenchymal lung disease. J Comput Assist Tomogr. 1991;15:948–52.

    Article  CAS  PubMed  Google Scholar 

  202. Farrelly CA. Wegener’s granulomatosis: a radiological review of the pulmonary manifestations at initial presentation and during relapse. Clin Radiol. 1982;33:545–51.

    Article  CAS  PubMed  Google Scholar 

  203. Wadsworth DT, Siegel MJ, Day DL. Wegener’s granulomatosis in children: chest radiographic manifestations. AJR Am J Roentgenol. 1994;163:901–4.

    Article  CAS  PubMed  Google Scholar 

  204. Yousem SA. Bronchocentric injury in Wegener’s granulomatosis: a report of five cases. Hum Pathol. 1991;22:535–40.

    Article  CAS  PubMed  Google Scholar 

  205. Uner AH, Rozum-Slota B, Katzenstein AL. Bronchiolitis obliterans-organizing pneumonia (BOOP)-like variant of Wegener’s granulomatosis. A clinicopathologic study of 16 cases. Am J Surg Pathol. 1996;20:794–801.

    Article  CAS  PubMed  Google Scholar 

  206. Seo JB, Im JG, Chung JW, et al. Pulmonary vasculitis: the spectrum of radiological findings. Br J Radiol. 2000;73:1224–31.

    Article  CAS  PubMed  Google Scholar 

  207. Doyle DJ, Fanning NF, Silke CS, et al. Wegener’s granulomatosis of the main pulmonary arteries: imaging findings. Clin Radiol. 2003;58:329–31.

    Article  CAS  PubMed  Google Scholar 

  208. Cheah FK, Sheppard MN, Hansell DM. Computed tomography of diffuse pulmonary haemorrhage with pathological correlation. Clin Radiol. 1993;48:89–93.

    Article  CAS  PubMed  Google Scholar 

  209. Bicknell SG, Mason AC. Wegener’s granulomatosis presenting as cryptogenic fibrosing alveolitis on CT. Clin Radiol. 2000;55:890–1.

    Article  CAS  PubMed  Google Scholar 

  210. Screaton NJ, Sivasothy P, Flower CD, Lockwood CM. Tracheal involvement in Wegener’s granulomatosis: evaluation using spiral CT. Clin Radiol. 1998;53:809–15.

    Article  CAS  PubMed  Google Scholar 

  211. Summers RM, Aggarwal NR, Sneller MC, et al. CT virtual bronchoscopy of the central airways in patients with Wegener’s granulomatosis. Chest. 2002;121:242–50.

    Article  PubMed  Google Scholar 

  212. Polychronopoulos VS, Prakash UB, Golbin JM, Edell ES, Specks U. Airway involvement in Wegener’s granulomatosis. Rheum Dis Clin N Am. 2007;33:755–75, vi.

    Article  Google Scholar 

  213. Travis WD, Hoffman GS, Leavitt RY, Pass HI, Fauci AS. Surgical pathology of the lung in Wegener’s granulomatosis. Review of 87 open lung biopsies from 67 patients. Am J Surg Pathol. 1991;15:315–33.

    Article  CAS  PubMed  Google Scholar 

  214. Zerizer I, Tan K, Khan S, et al. Role of FDG-PET and PET/CT in the diagnosis and management of vasculitis. Eur J Radiol. 2010;73:504–9.

    Article  PubMed  Google Scholar 

  215. Soussan M, Abisror N, Abad S, et al. FDG-PET/CT in patients with ANCA-associated vasculitis: case-series and literature review. Autoimmun Rev. 2014;13:125–31.

    Article  PubMed  Google Scholar 

  216. Nelson DR, Johnson GB, Cartin-Ceba R, Specks U. Characterization of F-18 fluorodeoxyglucose PET/CT in granulomatosis with polyangiitis. Sarcoidosis Vasc Diffuse Lung Dis. 2016;32:342–52.

    PubMed  Google Scholar 

  217. Ito K, Minamimoto R, Yamashita H, et al. Evaluation of Wegener’s granulomatosis using 18F-fluorodeoxyglucose positron emission tomography/computed tomography. Ann Nucl Med. 2013;27:209–16.

    Article  PubMed  Google Scholar 

  218. Blockmans D, Stroobants S, Maes A, Mortelmans L. Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch. Am J Med. 2000;108:246–9.

    Article  CAS  PubMed  Google Scholar 

  219. Beggs AD, Hain SF. F-18 FDG-positron emission tomographic scanning and Wegener’s granulomatosis. Clin Nucl Med. 2002;27:705–6.

    Article  PubMed  Google Scholar 

  220. Blockmans D, Baeyens H, Van Loon R, Lauwers G, Bobbaers H. Periaortitis and aortic dissection due to Wegener’s granulomatosis. Clin Rheumatol. 2000;19:161–4.

    Article  CAS  PubMed  Google Scholar 

  221. Kemna MJ, Bucerius J, Drent M, et al. Aortic (1)(8)F-FDG uptake in patients suffering from granulomatosis with polyangiitis. Eur J Nucl Med Mol Imaging. 2015;42:1423–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  222. Chirinos JA, Tamariz LJ, Lopes G, et al. Large vessel involvement in ANCA-associated vasculitides: report of a case and review of the literature. Clin Rheumatol. 2004;23:152–9.

    Article  PubMed  Google Scholar 

  223. Grant SC, Levy RD, Venning MC, Ward C, Brooks NH. Wegener’s granulomatosis and the heart. Br Heart J. 1994;71:82–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  224. Korantzopoulos P, Papaioannides D, Siogas K. The heart in Wegener’s granulomatosis. Cardiology. 2004;102:7–10.

    Article  PubMed  Google Scholar 

  225. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116:488–98.

    Article  CAS  PubMed  Google Scholar 

  226. Morelli S, Gurgo Di Castelmenardo AM, Conti F, et al. Cardiac involvement in patients with Wegener’s granulomatosis. Rheumatol Int. 2000;19:209–12.

    Article  CAS  PubMed  Google Scholar 

  227. Goodfield NE, Bhandari S, Plant WD, Morley-Davies A, Sutherland GR. Cardiac involvement in Wegener’s granulomatosis. Br Heart J. 1995;73:110–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  228. Cocco G, Gasparyan AY. Myocardial ischemia in Wegener’s granulomatosis: coronary atherosclerosis versus vasculitis. Open Cardiovasc Med J. 2010;4:57–62.

    PubMed  PubMed Central  Google Scholar 

  229. Florian A, Slavich M, Blockmans D, Dymarkowski S, Bogaert J. Cardiac involvement in granulomatosis with polyangiitis (Wegener granulomatosis). Circulation. 2011;124:342–4.

    Article  Google Scholar 

  230. Giollo A, Dumitru RB, Swoboda PP, et al. Cardiac magnetic resonance imaging for the detection of myocardial involvement in granulomatosis with polyangiitis. Int J Cardiovasc Imaging. 2020;37(3):1053–62.

    Article  PubMed  PubMed Central  Google Scholar 

  231. Pugnet G, Gouya H, Puechal X, et al. Cardiac involvement in granulomatosis with polyangiitis: a magnetic resonance imaging study of 31 consecutive patients. Rheumatology. 2017;56:947–56.

    Article  CAS  PubMed  Google Scholar 

  232. McGeoch L, Carette S, Cuthbertson D, et al. Cardiac involvement in granulomatosis with polyangiitis. J Rheumatol. 2015;42:1209–12.

    Article  PubMed  PubMed Central  Google Scholar 

  233. Ananthakrishnan L, Sharma N, Kanne JP. Wegener’s granulomatosis in the chest: high-resolution CT findings. AJR Am J Roentgenol. 2009;192:676–82.

    Article  PubMed  Google Scholar 

  234. Ugajin M, Miwa S, Suda T, Shirai M, Hayakawa H, Chida K. A case of pulmonary-limited Wegener granulomatosis mimicking bacterial pneumonia caused by Staphylococcus aureus. Nihon Kokyuki Gakkai Zasshi. 2011;49:309–14.

    PubMed  Google Scholar 

  235. Langford CA, et al. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener’s granulomatosis: extended follow-up and rate of relapse. Am J Med. 2003;114(6):463–9.

    Article  CAS  PubMed  Google Scholar 

  236. Villa-Forte A, et al. Substitution of methotrexate for cyclophosphamide in Wegener granulomatosis: a 12-year single-practice experience. Medicine. 2007;86(5):269–77.

    Article  CAS  PubMed  Google Scholar 

  237. Comarmond C, Cacoub P. Granulomatosis with polyangiitis (Wegener): clinical aspects and treatment. Autoimmun Rev. 2014;13(11):1121–5.

    Article  PubMed  Google Scholar 

  238. Martin F, et al. Side-effects of intravenous cyclophosphamide pulse therapy. Lupus. 1997;6(3):254–7.

    Article  CAS  PubMed  Google Scholar 

  239. Jones RB, et al. Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. Ann Rheum Dis. 2019;78(3):399–405.

    Article  CAS  PubMed  Google Scholar 

  240. Puéchal X, et al. Long-term outcomes among participants in the WEGENT trial of remission-maintenance therapy for granulomatosis with polyangiitis (Wegener’s) or microscopic polyangiitis. Arthritis Rheumatol. 2016;68(3):690–701.

    Article  PubMed  Google Scholar 

  241. Hiemstra TF, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA. 2010;304(21):2381–8.

    Article  CAS  PubMed  Google Scholar 

  242. Guillevin L, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771–80.

    Article  PubMed  Google Scholar 

  243. Jayne DR, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18(7):2180–8.

    Article  CAS  PubMed  Google Scholar 

  244. Walsh M, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020;382(7):622–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  245. Gómez-Puerta JA, et al. Antineutrophil cytoplasmic antibody-associated vasculitides and respiratory disease. Chest. 2009;136(4):1101–11.

    Article  PubMed  Google Scholar 

  246. Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol. 1951;27(2):277–301.

    CAS  PubMed  PubMed Central  Google Scholar 

  247. Vaglio A, et al. IgG4 immune response in Churg-Strauss syndrome. Ann Rheum Dis. 2012;71(3):390–3.

    Article  CAS  PubMed  Google Scholar 

  248. Mahr A, et al. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener’s granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum. 2004;51(1):92–9.

    Article  PubMed  Google Scholar 

  249. Mahr A, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): evolutions in classification, etiopathogenesis, assessment and management. Curr Opin Rheumatol. 2014;26(1):16–23.

    Article  CAS  PubMed  Google Scholar 

  250. Vaglio A, Buzio C, Zwerina J. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): state of the art. Allergy. 2013;68(3):261–73.

    Article  CAS  PubMed  Google Scholar 

  251. Cottin V, et al. Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): A study of 157 patients by the Groupe d’Etudes et de Recherche sur les Maladies Orphelines Pulmonaires and the European Respiratory Society Taskforce on eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Autoimmun Rev. 2017;16(1):1–9.

    Article  CAS  PubMed  Google Scholar 

  252. Zwerina J, et al. The emergence of antineutrophil cytoplasmic antibodies may precede the clinical onset of Churg-Strauss syndrome. Arthritis Rheum. 2009;60(2):626–7.

    Article  PubMed  Google Scholar 

  253. Mouthon L, Dunogue B, Guillevin L. Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named Churg-Strauss syndrome). J Autoimmun. 2014;48-49:99–103.

    Article  CAS  PubMed  Google Scholar 

  254. Gioffredi A, et al. Eosinophilic granulomatosis with polyangiitis: an overview. Front Immunol. 2014;5:549.

    Article  PubMed  PubMed Central  Google Scholar 

  255. Choi YH, Im JG, Han BK, Kim JH, Lee KY, Myoung NH. Thoracic manifestation of Churg-Strauss syndrome: radiologic and clinical findings. Chest. 2000;117:117–24.

    Article  CAS  PubMed  Google Scholar 

  256. Szczeklik W, Sokolowska B, Mastalerz L, et al. Pulmonary findings in Churg-Strauss syndrome in chest X-rays and high resolution computed tomography at the time of initial diagnosis. Clin Rheumatol. 2010;29:1127–34.

    Article  PubMed  Google Scholar 

  257. Worthy SA, Muller NL, Hansell DM, Flower CD. Churg-Strauss syndrome: the spectrum of pulmonary CT findings in 17 patients. AJR Am J Roentgenol. 1998;170:297–300.

    Article  CAS  PubMed  Google Scholar 

  258. Silva CI, Muller NL, Fujimoto K, Johkoh T, Ajzen SA, Churg A. Churg-Strauss syndrome: high resolution CT and pathologic findings. J Thorac Imaging. 2005;20:74–80.

    Article  PubMed  Google Scholar 

  259. Yilmaz I, et al. Clinical and serological features of eosinophilic and vasculitic phases of eosinophilic granulomatosis with polyangiitis: a case series of 15 patients. Turk Thorac J. 2017;18(3):72–7.

    Article  PubMed  PubMed Central  Google Scholar 

  260. Dennert RM, et al. Cardiac involvement in Churg-Strauss syndrome. Arthritis Rheum. 2010;62(2):627–34.

    PubMed  Google Scholar 

  261. Petersen H, et al. Manifestation of eosinophilic granulomatosis with polyangiitis in head and neck. Rhinology. 2015;53(3):277–85.

    Article  PubMed  Google Scholar 

  262. Bacciu A, et al. Ear, nose and throat manifestations of Churg-Strauss syndrome. Acta Otolaryngol. 2006;126(5):503–9.

    Article  PubMed  Google Scholar 

  263. Nakamoto K, et al. Comparison of findings on thoracic computed tomography with the severity and duration of bronchial asthma in patients with eosinophilic granulomatosis with polyangiitis. Respir Med. 2018;139:101–5.

    Article  PubMed  Google Scholar 

  264. Allenbach Y, et al. High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener’s granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis. 2009;68(4):564–7.

    Article  CAS  PubMed  Google Scholar 

  265. Ribi C, et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum. 2008;58(2):586–94.

    Article  CAS  PubMed  Google Scholar 

  266. Cohen P, et al. Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum. 2007;57(4):686–93.

    Article  CAS  PubMed  Google Scholar 

  267. Groh M, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med. 2015;26(7):545–53.

    Article  PubMed  Google Scholar 

  268. Pagnoux C, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359(26):2790–803.

    Article  CAS  PubMed  Google Scholar 

  269. Kim S, et al. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol. 2010;125(6):1336–43.

    Article  CAS  PubMed  Google Scholar 

  270. Samson M, et al. Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials. J Autoimmun. 2013;43:60–9.

    Article  PubMed  Google Scholar 

  271. Chung SA, Seo P. Microscopic polyangiitis. Rheum Dis Clin N Am. 2010;36(3):545–58.

    Article  Google Scholar 

  272. Sinico RA, Radice A. Antineutrophil cytoplasmic antibodies (ANCA) testing: detection methods and clinical application. Clin Exp Rheumatol. 2014;32(3 Suppl 82):S112–7.

    PubMed  Google Scholar 

  273. Watts RA, et al. The contrasting epidemiology of granulomatosis with polyangiitis (Wegener’s) and microscopic polyangiitis. Rheumatology. 2012;51(5):926–31.

    Article  PubMed  PubMed Central  Google Scholar 

  274. Kallenberg CG, Heeringa P, Stegeman CA. Mechanisms of disease: pathogenesis and treatment of ANCA-associated vasculitides. Nat Clin Pract Rheumatol. 2006;2(12):661–70.

    Article  CAS  PubMed  Google Scholar 

  275. Guilpain P, et al. Pathogenic effects of antimyeloperoxidase antibodies in patients with microscopic polyangiitis. Arthritis Rheum. 2007;56(7):2455–63.

    Article  CAS  PubMed  Google Scholar 

  276. Hogan SL, et al. Silica exposure in anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and lupus nephritis. J Am Soc Nephrol. 2001;12(1):134–42.

    Article  PubMed  Google Scholar 

  277. Sinico RA, Guillevan L. Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis. Ann Rheum Dis. 2020;2020:131–46.

    Google Scholar 

  278. Schirmer JH, et al. Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort. Rheumatology (Oxford). 2016;55(1):71–9.

    Article  PubMed  Google Scholar 

  279. Zhang W, et al. Clinical analysis of nervous system involvement in ANCA-associated systemic vasculitides. Clin Exp Rheumatol. 2009;27(1 Suppl 52):S65–9.

    CAS  PubMed  Google Scholar 

  280. Ahn JK, et al. Clinical features and outcome of microscopic polyangiitis under a new consensus algorithm of ANCA-associated vasculitides in Korea. Rheumatol Int. 2012;32(10):2979–86.

    Article  PubMed  Google Scholar 

  281. Guillevin L, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum. 1999;42(3):421–30.

    Article  CAS  PubMed  Google Scholar 

  282. Collins CE, Quismorio FP Jr. Pulmonary involvement in microscopic polyangiitis. Curr Opin Pulm Med. 2005;11(5):447–51.

    Article  PubMed  Google Scholar 

  283. Lauque D, et al. Microscopic polyangiitis with alveolar hemorrhage. A study of 29 cases and review of the literature. Groupe d’Etudes et de Recherche sur les Maladies “Orphelines” Pulmonaires (GERMOP). Medicine. 2000;79(4):222–33.

    Article  CAS  PubMed  Google Scholar 

  284. Gomez-Puerta JA, et al. Interstitial lung disease as a presenting manifestation of microscopic polyangiitis successfully treated with mycophenolate mofetil. Clin Exp Rheumatol. 2009;27(1):166–7.

    CAS  PubMed  Google Scholar 

  285. Tan JA, et al. Mortality in ANCA-associated vasculitis: a meta-analysis of observational studies. Ann Rheum Dis. 2017;76(9):1566–74.

    Article  PubMed  Google Scholar 

  286. Hellmark T, et al. Comparison of anti-GBM antibodies in sera with or without ANCA. J Am Soc Nephrol. 1997;8(3):376–85.

    Article  CAS  PubMed  Google Scholar 

  287. Ball JA, Young KR Jr. Pulmonary manifestations of Goodpasture's syndrome. Antiglomerular basement membrane disease and related disorders. Clin Chest Med. 1998;19(4):777–91. ix

    Article  CAS  PubMed  Google Scholar 

  288. Greco A, et al. Goodpasture’s syndrome: a clinical update. Autoimmun Rev. 2015;14(3):246–53.

    Article  PubMed  Google Scholar 

  289. Pusey CD. Anti-glomerular basement membrane disease. Kidney Int. 2003;64(4):1535–50.

    Article  PubMed  Google Scholar 

  290. Phelps RG, Rees AJ. The HLA complex in Goodpasture's disease: a model for analyzing susceptibility to autoimmunity. Kidney Int. 1999;56(5):1638–53.

    Article  CAS  PubMed  Google Scholar 

  291. Stevenson A, et al. Biochemical markers of basement membrane disturbances and occupational exposure to hydrocarbons and mixed solvents. QJM. 1995;88(1):23–8.

    CAS  PubMed  Google Scholar 

  292. Rutgers A, et al. High affinity of anti-GBM antibodies from Goodpasture and transplanted Alport patients to alpha3(IV)NC1 collagen. Kidney Int. 2000;58(1):115–22.

    Article  CAS  PubMed  Google Scholar 

  293. Hudson BG, et al. Alport’s syndrome, Goodpasture’s syndrome, and type IV collagen. N Engl J Med. 2003;348(25):2543–56.

    Article  CAS  PubMed  Google Scholar 

  294. Tipping PG, et al. Immune modulation with interleukin-4 and interleukin-10 prevents crescent formation and glomerular injury in experimental glomerulonephritis. Eur J Immunol. 1997;27(2):530–7.

    Article  CAS  PubMed  Google Scholar 

  295. Liang D, et al. Clinicopathological features and outcome of antibody-negative anti-glomerular basement membrane disease. J Clin Pathol. 2019;72(1):31–7.

    Article  CAS  PubMed  Google Scholar 

  296. Gulati K, McAdoo SP. Anti-Glomerular Basement Membrane Disease. Rheum Dis Clin N Am. 2018;44(4):651–73.

    Article  Google Scholar 

  297. Bolton WK. Goodpasture’s syndrome. Kidney Int. 1996;50(5):1753–66.

    Article  CAS  PubMed  Google Scholar 

  298. Bolton WK. Rapidly progressive glomerulonephritis. Semin Nephrol. 1996;16(6):517–26.

    CAS  PubMed  Google Scholar 

  299. Peters DK, et al. Treatment and prognosis in antibasement membrane antibody-mediated nephritis. Transplant Proc. 1982;14(3):513–21.

    CAS  PubMed  Google Scholar 

  300. Levy JB, et al. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med. 2001;134(11):1033–42.

    Article  CAS  PubMed  Google Scholar 

  301. van Daalen EE, et al. Predicting outcome in patients with anti-GBM glomerulonephritis. Clin J Am Soc Nephrol. 2018;13(1):63–72.

    Article  PubMed  Google Scholar 

  302. Jindal KK. Management of idiopathic crescentic and diffuse proliferative glomerulonephritis: evidence-based recommendations. Kidney Int Suppl. 1999;70:S33–40.

    Article  CAS  PubMed  Google Scholar 

  303. Tang W, et al. Anti-glomerular basement membrane antibody disease is an uncommon cause of end-stage renal disease. Kidney Int. 2013;83(3):503–10.

    Article  CAS  PubMed  Google Scholar 

  304. Zhang Y, et al. Clinical characteristics and prognosis of idiopathic pulmonary hemosiderosis in pediatric patients. J Int Med Res. 2019;47(1):293–302.

    Article  PubMed  Google Scholar 

  305. Chen XY, Sun JM, Huang XJ. Idiopathic pulmonary hemosiderosis in adults: review of cases reported in the latest 15 years. Clin Respir J. 2017;11(6):677–81.

    Article  PubMed  Google Scholar 

  306. Saha BK. Idiopathic pulmonary hemosiderosis: a state of the art review. Respir Med. 2021;176:106234.

    Article  PubMed  Google Scholar 

  307. Agarwal R, Aggarwal AN, Gupta D. Lane-Hamilton syndrome: simultaneous occurrence of coeliac disease and idiopathic pulmonary haemosiderosis. Intern Med J. 2007;37(1):65–7.

    Article  CAS  PubMed  Google Scholar 

  308. Salih ZN, Akhter A, Akhter J. Specificity and sensitivity of hemosiderin-laden macrophages in routine bronchoalveolar lavage in children. Arch Pathol Lab Med. 2006;130(11):1684–6.

    Article  CAS  PubMed  Google Scholar 

  309. Kabra SK, et al. Idiopathic pulmonary hemosiderosis: clinical profile and follow up of 26 children. Indian Pediatr. 2007;44(5):333–8.

    CAS  PubMed  Google Scholar 

  310. Saeed MM, et al. Prognosis in pediatric idiopathic pulmonary hemosiderosis. Chest. 1999;116(3):721–5.

    Article  CAS  PubMed  Google Scholar 

  311. Milman N, Pedersen FM. Idiopathic pulmonary haemosiderosis. Epidemiology, pathogenic aspects and diagnosis. Respir Med. 1998;92(7):902–7.

    Article  CAS  PubMed  Google Scholar 

  312. Mukai Y, Agatsuma T, Ideura G. Early diagnosis of idiopathic pulmonary haemosiderosis: increased haemosiderin-laden macrophages in repeat bronchoscopy. Respirol Case Rep. 2018;6(3):e00304.

    Article  PubMed  PubMed Central  Google Scholar 

  313. Ioachimescu OC, Sieber S, Kotch A. Idiopathic pulmonary haemosiderosis revisited. Eur Respir J. 2004;24(1):162–70.

    Article  CAS  PubMed  Google Scholar 

  314. Primack SL, Miller RR, Muller NL. Diffuse pulmonary hemorrhage: clinical, pathologic, and imaging features. AJR Am J Roentgenol. 1995;164:295–300.

    Article  CAS  PubMed  Google Scholar 

  315. Cortese G, Nicali R, Placido R, Gariazzo G, Anro P. Radiological aspects of diffuse alveolar haemorrhage. Radiol Med. 2008;113:16–28.

    Article  CAS  PubMed  Google Scholar 

  316. Bronson SM. Idiopathic pulmonary hemosiderosis in adults: report of a case and review of the literature. Am J Roentgenol Radium Therapy, Nucl Med. 1960;83:260–73.

    CAS  Google Scholar 

  317. Niimi A, Amitani R, Kurasawa T, et al. Two cases of idiopathic pulmonary hemosiderosis: analysis of chest CT findings. Nihon Kyobu Shikkan Gakkai Zasshi. 1992;30:1749–55.

    CAS  PubMed  Google Scholar 

  318. Silva P, Ferreira PG. Idiopathic pulmonary hemosiderosis: Hemorrhagic flare after 6 years of remission. Rev Port Pneumol. 2017;23:368–9.

    CAS  PubMed  Google Scholar 

  319. Gencer M, Ceylan E, Bitiren M, Koc A. Two sisters with idiopathic pulmonary hemosiderosis. Can Respir J. 2007;14:490–3.

    Article  PubMed  PubMed Central  Google Scholar 

  320. Miwa S, Imokawa S, Kato M, et al. Prognosis in adult patients with idiopathic pulmonary hemosiderosis. Intern Med. 2011;50:1803–8.

    Article  PubMed  Google Scholar 

  321. Kahraman H, Koksal N, Ozkan F. Eight years follow-up of a case with idiopathic pulmonary hemosiderosis after corticosteroid therapy. N Am J Med Sci. 2012;4:49–51.

    Article  PubMed  PubMed Central  Google Scholar 

  322. de Klerk KD, Bau S, Gunther G. Diffuse pulmonary small nodular and patchy infiltrates on chest X-ray with hemoptysis: TB or not TB?-a call for scale up of respiratory medicine services in African TB high burden countries: a case of idiopathic pulmonary hemosiderosis. Pan Afr Med J. 2018;30:121.

    Article  PubMed  PubMed Central  Google Scholar 

  323. Chen CH, Yang HB, Chiang SR, Wang PC. Idiopathic pulmonary hemosiderosis: favorable response to corticosteroids. J Chin Med Assoc. 2008;71:421–4.

    Article  PubMed  Google Scholar 

  324. Engelke C, Schaefer-Prokop C, Schirg E, Freihorst J, Grubnic S, Prokop M. High-resolution CT and CT angiography of peripheral pulmonary vascular disorders. Radiographics. 2002;22:739–64.

    Article  PubMed  Google Scholar 

  325. Khorashadi L, Wu CC, Betancourt SL, Carter BW. Idiopathic pulmonary haemosiderosis: spectrum of thoracic imaging findings in the adult patient. Clin Radiol. 2015;70:459–65.

    Article  CAS  PubMed  Google Scholar 

  326. Marchiori E, Souza AS Jr, Franquet T, Muller NL. Diffuse high-attenuation pulmonary abnormalities: a pattern-oriented diagnostic approach on high-resolution CT. AJR Am J Roentgenol. 2005;184:273–82.

    Article  PubMed  Google Scholar 

  327. Nickol KH. Idiopathic pulmonary haemosiderosis presenting with spontaneous pneumothorax. Tubercle. 1960;41:216–8.

    Article  CAS  PubMed  Google Scholar 

  328. Pacheco A, Casanova C, Fogue L, Sueiro A. Long-term clinical follow-up of adult idiopathic pulmonary hemosiderosis and celiac disease. Chest. 1991;99:1525–6.

    Article  CAS  PubMed  Google Scholar 

  329. Toro K, Herjavecz I, Vereckei E, Kovacs M. Fatal idiopathic pulmonary haemosiderosis in association with pregnancy - medico-legal evaluation. J Forensic Legal Med. 2012;19:101–4.

    Article  Google Scholar 

  330. Turner-Warwick M, Dewar A. Pulmonary haemorrhage and pulmonary haemosiderosis. Clin Radiol. 1982;33:361–70.

    Article  CAS  PubMed  Google Scholar 

  331. Tzouvelekis A, Ntolios P, Oikonomou A, et al. Idiopathic pulmonary hemosiderosis in adults: a case report and review of the literature. Case Rep Med. 2012;2012:267857.

    Article  PubMed  PubMed Central  Google Scholar 

  332. Yanagihara T, Yamamoto Y, Hamada N, et al. Recurrent idiopathic pulmonary hemosiderosis after long-term remission presented with Sjogren's syndrome: idiopathic no more? Respir Med Case Rep. 2018;25:68–72.

    PubMed  PubMed Central  Google Scholar 

  333. Engeler C. High-resolution CT of airspace nodules in idiopathic pulmonary hemosiderosis. Eur Radiol. 1995;5:663–5.

    Article  Google Scholar 

  334. Buschman DL, Ballard R. Progressive massive fibrosis associated with idiopathic pulmonary hemosiderosis. Chest. 1993;104:293–5.

    Article  CAS  PubMed  Google Scholar 

  335. Barrera AM, Vargas L. Idiopathic pulmonary hemosiderosis with dendriform pulmonary ossification. Biomedica. 2016;36:504–8.

    Article  PubMed  Google Scholar 

  336. Harte S, McNicholas WT, Donnelly SC, Dodd JD. Honeycomb cysts in idiopathic pulmonary haemosiderosis: high-resolution CT appearances in two adults. Br J Radiol. 2008;81:e295–8.

    Article  CAS  PubMed  Google Scholar 

  337. Reyes NS, Arteaga V. Idiopathic pulmonary hemosiderosis. Southwest J Pulm Crit Care. 2014;9:30–1.

    Article  Google Scholar 

  338. Rubin GD, Edwards DK 3rd, Reicher MA, Doemeny JM, Carson SH. Diagnosis of pulmonary hemosiderosis by MR imaging. AJR Am J Roentgenol. 1989;152:573–4.

    Article  CAS  PubMed  Google Scholar 

  339. Tanaka AM, Murayama S, Sakai S, Masuda K, Ohga S, Ueda K. A case of idiopathic pulmonary hemosiderosis, MR imaging; case report. Jpn J Clin Radiol. 1994;39:1735–7.

    Google Scholar 

  340. Bordow RA, Ries AL, Morris TA. Manual of clinical problems in pulmonary medicine- Idiopathic pulmonary hemosiderosis. 6th ed. Philadelphia: Lippincott Williams and Wilkins; 2015. p. 527–9.

    Google Scholar 

  341. Romei CTL, Tavanti L, Miedema J, Fiorina S, Massimo M, Wielopolski P, Tiddens Falaschi F, Cie P. The use of chest magnetic resonance imaging in interstitial lung disease: a systematic review. Eur Respir Rev. 2018;27:180062.

    Article  PubMed  PubMed Central  Google Scholar 

  342. Taussig LM, Landau LI, Le Souef PN. Pediatric respiratory medicine. 2nd ed. Philadelphia: Mosby/Elsevier; 2008. p. 1.

    Google Scholar 

  343. DeGowin RL, Sorensen LB, Charleston DB, Gottschalk A, Greenwald JH. Retention of radioiron in the lungs of a woman with idiopathic pulmonary hemosiderosis. Ann Intern Med. 1968;69:1213–20.

    Article  CAS  PubMed  Google Scholar 

  344. Miller T, Tanaka T. Nuclear scan of pulmonary hemorrhage in idiopathic pulmonary hemosiderosis. AJR Am J Roentgenol. 1979;132:120–1.

    Article  CAS  PubMed  Google Scholar 

  345. Chen CH, et al. Idiopathic pulmonary hemosiderosis: favorable response to corticosteroids. J Chin Med Assoc. 2008;71(8):421–4.

    Article  PubMed  Google Scholar 

  346. Colombo JL, Stolz SM. Treatment of life-threatening primary pulmonary hemosiderosis with cyclophosphamide. Chest. 1992;102(3):959–60.

    Article  CAS  PubMed  Google Scholar 

  347. Rossi GA, et al. Long-term prednisone and azathioprine treatment of a patient with idiopathic pulmonary hemosiderosis. Pediatr Pulmonol. 1992;13(3):176–80.

    Article  CAS  PubMed  Google Scholar 

  348. Le Clainche L, et al. Long-term outcome of idiopathic pulmonary hemosiderosis in children. Medicine. 2000;79(5):318–26.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pulmonary, Critical Care and Sleep Medicine, University of Texas – McGovern Medical School, Houston, TX, USA

    Maryam Kaous & Lilit A. Sargsyan

  2. Department of Radiology, The University of Texas Medical Branch, UTMB, Galveston, TX, USA

    Diana Palacio

  3. Department of Radiology, University of New Mexico HSC, Albuquerque, NM, USA

    Jennifer A. Febbo & Loren Ketai

  4. Department of Radiology, Harvard University, Massachusetts General Hospital, Cambridge, MA, USA

    Matthew D. Gilman

  5. Department of Thoracic Imaging, The University of Texas MD Anderson Cancer, Houston, TX, USA

    Patricia M. de Groot & Mylene T. Truong

  6. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Cesar A. Moran

Authors
  1. Maryam Kaous
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lilit A. Sargsyan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Diana Palacio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jennifer A. Febbo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Loren Ketai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Matthew D. Gilman
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Patricia M. de Groot
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mylene T. Truong
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Cesar A. Moran
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mylene T. Truong .

Editor information

Editors and Affiliations

  1. Department of Pathology, The University of Texas MD Anderson Cancer, Houston, TX, USA

    Cesar A. Moran

  2. Department of Thoracic Imaging, The University of Texas MD Anderson Cancer, Houston, TX, USA

    Mylene T. Truong

  3. Department of Thoracic Imaging, The University of Texas MD Anderson Cancer, Houston, TX, USA

    Patricia M. de Groot

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kaous, M. et al. (2023). Pulmonary Vasculitides. In: Moran, C.A., Truong, M.T., de Groot, P.M. (eds) The Thorax. Springer, Cham. https://doi.org/10.1007/978-3-031-21040-2_21

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-21040-2_21

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-21039-6

  • Online ISBN: 978-3-031-21040-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation